Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13002
Country/Region: Uganda
Year: 2016
Main Partner: United Nations High Commissioner for Refugees
Main Partner Program: NA
Organizational Type: Multi-lateral Agency
Funding Agency: enumerations.State/PRM
Total Funding: $741,823 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $99,865
Care: Orphans and Vulnerable Children (HKID) $169,720
Care: TB/HIV (HVTB) $25,047
Care: Pediatric Care and Support (PDCS) $48,807
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $65,477
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $92,350
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $30,281
Treatment: Adult Treatment (HTXS) $195,226
Treatment: Pediatric Treatment (PDTX) $15,050
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 20
GEND_GBV Age/Sex: <10 Male 2017 12
GEND_GBV Age/Sex: 10-14 Female 2017 52
GEND_GBV Age/Sex: 10-14 Male 2017 12
GEND_GBV Age/Sex: 15-19 Female 2017 96
GEND_GBV Age/Sex: 15-19 male 2017 20
GEND_GBV Age/Sex: 20-24 Female 2017 89
GEND_GBV Age/Sex: 20-24 Male 2017 20
GEND_GBV Age/Sex: 25-49 Female 2017 38
GEND_GBV Age/Sex: 25-49 Male 2017 20
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 35
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 85
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 294
GEND_GBV Number of people receiving post-GBV care 2017 379
GEND_GBV Sum of Age/Sex Disaggregates 2017 96
HTS_TST Age/sex: <1 2017 291
HTS_TST Age/sex: 1-9 2017 956
HTS_TST Age/sex: 10-14 Female 2017 825
HTS_TST Age/sex: 10-14 Male 2017 826
HTS_TST Age/sex: 15-19 Female 2017 4,715
HTS_TST Age/sex: 15-19 Male 2017 4,839
HTS_TST Age/sex: 20-24 Female 2017 7,073
HTS_TST Age/sex: 20-24 Male 2017 7,258
HTS_TST Age/sex: 25-49 Female 2017 10,844
HTS_TST Age/sex: 25-49 Male 2017 11,129
HTS_TST Age/sex: 50+ Female 2017 944
HTS_TST Age/sex: 50+ Male 2017 968
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,448
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,450
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 23,576
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 24,194
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 50,668
HTS_TST Service Delivery Point (Facility): Index testing 2017 2,080
HTS_TST Service Delivery Point (Facility): Inpatient 2017 8,263
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,911
HTS_TST Service Delivery Point (Facility): Outpatient 2017 18,788
HTS_TST Service Delivery Point (Facility): Pediatric 2017 2,496
HTS_TST Service Delivery Point (Facility): PMTCT 2017 9,275
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 337
HTS_TST Service Delivery Point (Facility): VMMC 2017 6,518
HTS_TST Sum of Age/Sex disaggregates 2017 49,421
HTS_TST Sum of Aggregated Age/Sex <15 2017 2,898
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 47,770
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 50,668
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 32
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 33
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 195
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 140
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 291
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 214
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 445
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 328
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 39
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 27
HTS_TST_POS Test Result by Age: Positive: <1 2017 12
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 38
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 56
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 59
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 970
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 709
PMTCT_ART Already on ART at beginning of current pregnancy 2017 203
PMTCT_ART New on ART 2017 146
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 6,370
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 230
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 65
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 2
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 11
PMTCT_EID Sum of Infant Age disaggregates 2017 295
PMTCT_STAT By: Known positives at entry 2017 193
PMTCT_STAT By: Number of new positives identified 2017 176
PMTCT_STAT Number of new ANC and L&D clients 2017 6,534
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 6,370
PMTCT_STAT Sum of Positives Status disaggregates 2017 369
PP_PREV Aggregated Age/sex: <15 Female 2017 180
PP_PREV Aggregated Age/sex: <15 Male 2017 167
PP_PREV Aggregated Age/sex: 15+ Female 2017 212
PP_PREV Aggregated Age/sex: 15+ Male 2017 212
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 771
PP_PREV Total number of people in the target population 2017 2,231
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 10
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 23
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 33
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 33
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 575
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 59
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 172
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 344
TB_SCREENDX Screen Result: Screened Positive for TB 2017 144
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 4,356
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 2,239
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 311
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 273
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 7,179
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 57
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 107
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 173
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 173
TX_CURR Age/Sex: <1 2017 22
TX_CURR Age/Sex: <1-9 2017 140
TX_CURR Age/Sex: 10-14 Female 2017 227
TX_CURR Age/Sex: 10-14 Male 2017 195
TX_CURR Age/Sex: 15-19 Female 2017 218
TX_CURR Age/Sex: 15-19 Male 2017 68
TX_CURR Age/Sex: 20-24 Female 2017 1,002
TX_CURR Age/Sex: 20-24 Male 2017 447
TX_CURR Age/Sex: 25-49 Female 2017 2,918
TX_CURR Age/Sex: 25-49 Male 2017 1,611
TX_CURR Age/Sex: 50+ Female 2017 218
TX_CURR Age/Sex: 50+ Male 2017 113
TX_CURR Aggregated Age/Sex: <15 Female 2017 311
TX_CURR Aggregated Age/Sex: <15 Male 2017 273
TX_CURR Aggregated Age/Sex: 15+ Female 2017 4,356
TX_CURR Aggregated Age/Sex: 15+ Male 2017 2,239
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 7,179
TX_CURR Sum of age/sex disaggregates 2017 286
TX_CURR Sum of Aggregated Age/Sex <15 2017 584
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 6,595
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 7,179
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 73
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 66
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,054
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,061
TX_NEW By Age/Sex: <1 2017 5
TX_NEW By Age/Sex: 1-9 2017 34
TX_NEW By Age/Sex: 10-14 Female 2017 53
TX_NEW By Age/Sex: 10-14 Male 2017 47
TX_NEW By Age/Sex: 15-19 Female 2017 103
TX_NEW By Age/Sex: 15-19 Male 2017 33
TX_NEW By Age/Sex: 20-24 Female 2017 473
TX_NEW By Age/Sex: 20-24 Male 2017 213
TX_NEW By Age/Sex: 25-49 Female 2017 1,377
TX_NEW By Age/Sex: 25-49 Male 2017 764
TX_NEW By Age/Sex: 50+ Female 2017 101
TX_NEW By Age/Sex: 50+ Male 2017 51
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 3,254
TX_NEW Sum of Age/Sex disaggregates 2017 3,215
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 3,254
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 5,743
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 5,169
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 225
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 195
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 3,135
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,614
TX_PVLS Numerator: Indication: Routine 2017 5,169
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 249
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 219
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 3,485
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,790
TX_PVLS_den Denominator: Indication: Routine 2017 5,743
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 57
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 162
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 376
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 129
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 16
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 19
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 243
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 522
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 800
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 899
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 63
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 116
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 185
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 422
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 17
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 276
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 586
VMMC_CIRC By Age: 10-14 2017 2,540
VMMC_CIRC By Age: 15-19 2017 1,890
VMMC_CIRC By Age: 20-24 2017 912
VMMC_CIRC By Age: 25-29 2017 522
VMMC_CIRC By Age: 30-49 2017 522
VMMC_CIRC By Age: 50+ 2017 132
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 6,518
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 6,518
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 6,518
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 5,474